Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.0152W HIGH $1.31
Volume
484.03 K
Value Traded
4.26 K
Short % Float
0.01%
Days to Cover
1.0
-8.84%Week
-17.5%1 Month
-25%3 Month
-64.89%6 Month
-99.04%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.56 M
EPS (TTM)
-1.10
P/E Ratio
-
Ent. Value
-3.54 M
Total Shares
39.74 M
Float Shares
28.69 M
Insiders
0.03%
Institutions
0.31%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
VIRX Catalyst Timeline
Dated clinical, regulatory and corporate events for Viracta Therapeutics, Inc.
Past FDA Catalysts and PDUFA Decisions
How VIRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
12
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VRx-3996 and valganciclovir Small moleculeCompletedNCT03397706 | Epstein-Barr Virus-Associated Lymphoma | Phase 1/2 | COMPLETED | 64 | May 4, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every VIRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Nana-val | EBV-associated cancers | Phase 1b/2 | 2023-10-04 | overall response rate PTCL: 40%; complete response rate PTCL: 40%; median duration of response PTCL: 17.3 months; overall response rate DLBCL: 67%; median duration of response DLBCL: not yet reached; duration of response DLBCL: out to 42 monthsRead More | Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers Preliminary clinical data from patients with relapsed/refractory EBV + peripheral T-cell lymphoma in the pivotal NRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| ROYSTON IVORDirector | Option | 25,219 839,741 held | $0.00 | 11/25/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in VIRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Samsara BioCapital, LLC | 0 % (-100 %) | 159.60 K | 689.71 K |
Ownership Trends
VIRX Short Interest
Shares sold short, counted twice a month.
0.01%
Short % of Float
of tradable shares sold short
14.3K
Shares Sold Short
+76.4% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
793.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VIRX ranks across every disease it competes in
Competitive Position is a premium feature
See how VIRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVIRX News
About Viracta Therapeutics, Inc.
Founded2005
BIOPHARMAWATCH ELITE PLUS
Trade the next VIRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime